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Abstract
The first chapter in this manuscript serves as an overview of the background,
significance, and theological framework of this study, comparison of papillary renal cell
carcinoma type 1 and type 2: a secondary analysis. The body of this work focuses on the topics
of the current knowledge, genetic variations and syndromes, demographics, increased risk
factors, and pathways associated with type 1 and type 2 papillary renal cell carcinoma.
The second chapter is a review of the literature to discuss the current working knowledge
on papillary renal cell carcinoma including genetic underpinnings, disease management and
histological subtyping. This chapter was designed to give clinicians a better working knowledge
on papillary renal cell carcinoma. The results of this review highlight the importance of
discovering discernible differences between type 1 and type 2 papillary renal cell carcinoma
tumors.
The third chapter is a review of the most common hereditary renal cell syndromes that
are associated with an increased risk of developing renal cell carcinomas. This review covered
Hereditary Leiomyomatosis and Renal Cell Cancer, a renal cancer syndrome that is characterized
by benign neoplasms and is associated with an increased risk of developing type 2 papillary renal
cell carcinoma. The results of this review highlighted the complex genetic nature of papillary
renal cell carcinoma and provided the background for a variable used in the secondary data
analysis.
The fourth chapter describes the dissertation work and was a secondary data analysis on
papillary renal cell carcinoma using The Cancer Genome Atlas – Cervical Kidney Renal
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Papillary Cell Carcinoma and cBioPortal databases. The analysis focused on determining the
epidemiological, increased risk factor and pathway preference differences between type 1 and
type 2 papillary renal cell carcinoma. The results of this study showed that while there are some
significant differences between tumor types, further studies are warranted.
The final chapter is a synthesis of all the manuscripts related to papillary renal cell
carcinoma type 1 and type 2 tumors. This chapter provides a cohesive discussion of all three
manuscripts and provides suggestions for future research specific to type 1 and type 2 papillary
renal cell carcinoma. The result of all three manuscripts is to better provide an understanding of
papillary renal cell carcinoma as a disease and to define differences between type 1 and type.
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Chapter I
Introduction
Statement of the Problem
Renal cell carcinoma (RCC) is among the top ten most commonly occurring cancers in
the United States. The American Cancer Society (ACS) estimates around 74,000 new cases will
be diagnosed and 15,000 deaths will occur from RCC in 2020 (ACS, 2020). Clear cell renal cell
carcinoma (ccRCC) is the most common RCC subtype and as such has been the focus of the
majority of RCC research. Specifically, known epidemiological data such as demographics and
increased risk factors, have been based on the ccRCC subtype.
Papillary renal cell carcinoma (PRCC) is the second most common RCC subtype
comprising 15-20% of total RCC cases (Pal et al. 2018). PRCC is considered a heterogenous
disease and is further divided into multiple subtypes, with the two most common subtypes being
type 1 and type 2. Current PRCC research has been dedicated to determining the cellular
molecular components of the disease, with no significant research distinguishing between type 1
and type 2 PRCC subtypes (MacLennan & Cheng 2020: Lineman et al 2015). However,
research has shown that the different PRCC subtypes have varying patient outcomes.
Specifically, type 1 tumors tend to be diagnosed at a lower grade and have a better prognosis
than type 2 tumors. Furthermore, there are numerous genetic variations in both PRCC tumor
subtypes that are not seen in other RCC subtypes, making traditional drug treatment therapies
ineffective (Lineman et al 2015; Ahrens et al. 2019).
There are significant gaps in the literature concerning other RCC subtypes in which
researchers are striving to address. Such gaps include understanding the epidemiology, genetics
and risk factors associated with subtypes other than ccRCC. The goal of this dissertation is to

1

expand the state of the science regarding type 1 and type 2 PRCC tumors and the genetic
relationships.
Papillary renal cell carcinoma (PRCC) is the second most common RCC subtype
comprising 15-20% of total RCC cases (Pal et al. 2018). PRCC is considered a heterogenous
disease and is further divided into multiple subtypes, with the two most common subtypes being
type 1 and type 2. Current PRCC research has been dedicated to determining the cellular
molecular components of the disease, with no significant research distinguishing between type 1
and type 2 PRCC subtypes (MacLennan & Cheng 2020: Lineman et al 2015). However,
research has shown that the different PRCC subtypes have varying patient outcomes.
Specifically, type 1 tumors tend to be diagnosed at a lower grade and have a better prognosis
than type 2 tumors. Furthermore, there are numerous genetic variations in both PRCC tumor
subtypes that are not seen in other RCC subtypes, making traditional drug treatment therapies
ineffective (Lineman et al 2015; Ahrens et al. 2019).
The aim of this research was to determine if there were significant discernible
differences, specifically demographics, increased risk factors and genetic pathway preferences
between type 1 and type 2 PRCC tumors. The premise for the research was to gain expanded
knowledge of type 1 and type 2 PRCC subtypes so clinicians will be able to better identify
patients at risk for each subtype and subsequently development appropriate evidence-based
treatment plans.
Significance of the Problem
PRCC is often difficult to detect with only 5% to 10% of patients presenting with
symptoms of hematuria, flank pain and palpable abdominal masses. Furthermore, these
symptoms generally occur in advanced stages of the disease when kidney function has been
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compromised (Maclennan & Cheng 2020; Diaz de Leon & Pedrosa 2018). The other 90 to 95%
of PRCC tumors are generally found via incidental findings during kidney imaging for other
maladies such as hypertension or chronic kidney disease. Traditionally, tumors that are
diagnosed early tend to be smaller, less invasive and have a better prognosis than tumors that are
found at more advanced stages. Additionally, PRCC type 1 tumors have higher survival rates
and more positive outcomes as compared to type 2 tumors (Grande & Fidler 2015; MacLennan
& Cheng 2020).
Treatment
Treatment options for PRCC remains limited with nephrectomy being the standard
strategy. Typically, nephrectomy involves the partial or total removal of the kidney, which can
results in decrease kidney function. Patients who undergo nephrectomies are at an increased risk
of developing hypertension and chronic kidney disease (Glazar et al. 2014). Up to 20% of
patients that undergo localized treatment or nephrectomy experience cancer reoccurrence. Even
with the reoccurrence rates, there are concerns that partial nephrectomies are too invasive. Thus,
surveillance is often recommended as an alternative. Recent technology advances have provided
less invasive procedures to help maintain proper kidney function, but not all patients are suitable
for these procedures. Currently, there are no successful adjuvant (after surgery) therapies to treat
RCCs (Redig et al. 2019; Chien et al. 2020). Targeted treatment therapies have been found to be
helpful in the effective treatment of RCCs. These therapies target cancer specific genes or
proteins and is the basis of precision cancer treatment. However, current drug therapy options are
designed for clear cell renal cell carcinoma and are not specific for treating PRCC. There are
several clinical trials in progress but no drug therapy specific to PRCC (Redig et al. 2018;
Dengina et al. 2017; Ahrens et al. 2019).
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Monetary Impact
Along with the physical impact of cancer, there is also a significant burden associated
with RCC. Currently, the United States has an annual cost of $600 million, up to $5.2 billion US
dollars for all cancers and the cost continues to rise. Specifically, technological advances have
increased the cost of localized treatments and nephrectomy for RCC, which can be $20,000 to
$50,000. The cost of nephrectomy does not include any additional treatments that may be
needed, such drug therapies or necessary dialysis (Jeong et al. 2019; Chien et al. 2020).
Moreover, drug treatment therapies have varying costs depending on the drug and whether the
drug is a first line or second line treatment therapy. First line treatments can $150,000 whereas
second line treatments cost $60,000 to $120,000. However, second line treatments are utilized in
conjunction with first line treatments which raises their cost to approximately $350,000.
Treatment costs increase with cancer metastasis since more aggressive treatments are needed
(Deniz et al. 2019; Chien et al. 2020). These costs reflect the cost of the drug therapy themselves,
and do not include doctor visits, lost wages or other costs associated with cancer treatments.
Providing a comprehensive understanding of the epidemiology of PRCC will allow
clinicians to distinguish between subtypes at earlier stages. Focusing on the individual risk
factors and preferred genetic pathways displayed by each of the two subtypes supports the next
stages of genetic research. This new avenue of research will ultimately supply vital criteria to
develop individualized treatment plans that will lower treatment costs and increase treatment
success rates.
Theoretical Framework Supporting the Primary Dissertation Problem/Issue
The theoretical framework for this research project is the integrative cancer theory. Given
that PRCC is a heterogenous disease that encompasses a large number of genetic variations,
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clinical and epidemiological features, the integrative cancer theory supports the research
directive. This theory was developed from the comprehensive integrative theory, which is widely
used in psychiatry. The integrative theory views illness, both mental and biological, as a complex
disease that needs to be viewed at multiple angles. The theory states that looking at illness from a
variety of perspectives will lead to more comprehensive and personalized treatment plans (Lake
2007; Lake 2008). The integrative cancer theory specifically includes three domains: genetic
variations, epidemiological factors and environmental risk factors. Each one of the three domains
adds to the metabolic imbalance between host and tumor, allowing further tumor proliferation
(Luo & Liu 2019). By looking at PRCC as a complicated disease with multiple components in
each domain, disease risk factors will be determined, and treatment plans will be personalized.
The integrative theory for cancer is utilized to conceptualize cancer as a linked genetic
disease. In this theory, chronic irritations, defined as any metabolic imbalance (including chronic
inflammation, unstable glucose levels and lack of vital nutrients), provoke tumors with genetic
alterations and rapid proliferative ability. These tumor cells reprogram their metabolic systems
and employ aerobic glycolysis to sustain the rapid growth. Further proliferation occurs in
patients with certain characteristics, such as advanced age, obesity, and diabetes (both Type I and
Type II). These co-existing conditions trigger a metabolic imbalance between the patient and
tumor resulting in catastrophe events of invasion, metastasis, and necrosis (Luo and Liu, 2019).
PRCC is a genetically linked disease that encompasses multiple genetic pathways which allow
cancer cells to override normal cell signaling. By overriding normal cytogenetic pathways,
PRCC tumors grow, invade surrounding tissue and kill normal cells (Maclennan & Cheng 2020).
Therefore, PRCC as a disease follows the conceptual model presented by the integrative cancer
theory.
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Fig. 1.1 Integrative Cancer Theory
This research views PRCC as a complex heterogenous disease that is not limited to one
risk factor or genetic pathway. Furthermore, this study sought to define differences in each of the
three domains as described in the integrative theory for cancer. Due to the complex genetic
nature of PRCC, genetic pathways were used to fulfil the first domain. Cancer cells will turn off
or increase the host and tumor metabolic imbalance on certain genes to manipulate cellular
pathways (Luo & Liu 2019). Therefore, looking at PRCC genetic pathways sufficiently satisfies
the conditions of the first domain. The second (epidemiological factors) and third
(environmental risk factors) domains were categorized as demographics and associated risk
factors specific for to this research study. The target demographic variable included in this
research were age, ethnicity, gender, and race. Each of these variables have the potential to
increase the tumor/host imbalance and promote tumor development. The associated risk factors
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examined were body mass index (BMI), smoking history, neoplasm (non-malignant tumor)
history, and malignancy history. The integrative cancer theory is appropriate to provide the
framework for this dissertation since this research looks at the three domains of PRCC as
described in the theory in an effort to identify differences between PRCC subtypes.
An Overview of the Important Literature
PRCC tumors are characterized by solid well-defined lesions in the renal papillae or
tubulopapillae that are formed by a single layer of cuboidal cells (Grande & Fidler 2015;
MacLennan & Cheng 2020). Furthermore, PRCC tumors tend to be multifocal (multiple tumors
arise from one tumor in the same location) and necrotic (dead renal cells are present in the
tumor). PRCC consists of multiple genetic variations and can be sporadic and hereditary
(inherited) with most cases being the sporadic form. Hereditary PRCC is most commonly
characterized by mutations in the oncogene Mesenchymal Epithelial Transition (MET), although
there are multiple genetic variations associated with both sporadic and hereditary PRCC
(MacLennan & Cheng 2020). PRCC subtypes are most frequently characterized by
histomorphological features, although recent studies suggest using cytomorphological structures
to better distinguish between subtypes. Type 1 PRCC tumors are defined as having a single layer
of cells with sparse basophilic cytoplasm and small round nuclei. Conversely, type 2 PRCC is
defined as a pseudostratified layer of cells with eosinophilic cytoplasm and large spherical nuclei
(MacLennan & Cheng 2020; Magers et al. 2019).
Risk factors associated with RCC are supported by current literature, though still limited
because they focus on the ccRCC subtype. The first category of risk factors are demographics
with certain factors associated with an increased risk for RCC. Research suggests that RCC is
less prevalent in women with men being diagnose Men have higher prevalence, 2:1, at a lower
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median age of diagnosis of 50-59 years compared to women. In fact, RCC risk increases with
age within all sexes until a plateau occurs around 70 years. RCC rates vary by ethnicity/race with
the lowest incidence seen in Asian Americans, 8.8 cases per 100,000 and the highest incidence
seen in African Americans, 17.5 cases per 100,000 (Hsieh et al. 2019; Diaz de Leon et al. 2017;
Howlader et al. 2020). Additionally, there are number of increased risk factors that increase an
individual’s chance of developing RCC such as increased Body Mass Index (BMI) and the use of
tobacco products. One study has shown that BMI and tobacco use were factors in at least half of
PRCC cases. Smoking cessation may decrease PRCC risk but limited to those who have quit for
ten years or longer (Hsieh et al. 2019; Diaz de Leon et al. 2017).
There are several renal cell cancer syndromes that predispose an individual to the
development of RCC. Not only do these renal cell cancer syndromes provide evidence for the
genetic variables used in this research study, many of them present with benign neoplasms.
BRCA1 Associated Protein-1 (BAP1) tumor predisposition syndrome, Birt-Hogg-Dubé
syndrome, and Cowden syndrome present with benign tumor growths with associated increased
risk for developing RCC. Another example is von Hippel-Lindau syndrome, which is the most
common renal cell cancer syndrome and characterized by variations in the Von Hippel–Lindau
Tumor Suppressor (VHL) gene (Paquin & Fasolino 2020). Additionally, there are numerous
genetic variations that have been associated with RCC. At least eleven genes have been linked to
hereditary RCC including, Folliculin (FLCN), Fumarate Hydratase (FH), Phosphatase and
Tensin Homolog (PTEN), Succinate Dehydrogenase Complex Iron Sulfur Subunit B (SDHB),
and TSC Complex Subunit 1 (TSC1). Variations in MET have been found in as many as 20% of
hereditary PRCC cases as well as in sporadic cases. MET variations have been seen in both type
1 and type 2 PRCC tumors (Hsieh et al. 2019; Albiges et al. 2015). However, genetic variations

8

in RCC are not limited to genetic mutations and include chromosomal copy number variations.
Type 1 PRCC shows copy number gains in chromosome 7, whereas type 2 PRCC show losses in
chromosome 9 (Modi & Singer 2016). Due to the large number of genetic variations, utilizing
genetic pathways may be a more efficient process for comparing type 1 and type 2 PRCC instead
of genetic sequencing. Utilizing genetic pathways will cover a larger number of genes allowing
the treatment of more patients at once and decreasing cost.
Three manuscripts have been submitted to fulfill the specific aims of this research
project. Collectively, the three manuscripts offer a comprehensive view of the differences
between type 1 and type 2 PRCC. The target audiences for these manuscripts have been direct
patient care clinicians, healthcare clinicians who directly provide patient care, in order to
advance their knowledge of the differences in epidemiology, risk factors and genetic pathways
associated with type 1 and type 2 PRCC. The following offers detailed information on the three
papers:
The first manuscript (Chapter 2) is entitled “Papillary Renal Cell Carcinoma:
Epidemiology, Subtype Classification, and Various Genetic Pathways of the Disease” (Under
Review). Papillary renal cell carcinoma (PRCC) is a subset of renal cell carcinoma (RCC).
PRCC is a heterogenous disease that consists of multiple subtypes, diverse genetic makeups, and
a continually changing epidemiology. Similarly, the management of PRCC reflects the
complexity of the disease. Clinicians should possess a basic knowledge of the subtype
classification, genetic pathways and epidemiology of PRCC in order to develop effective
management plans. This paper presented the current applicable knowledge of PRCC as it relates
to healthcare clinicians (Paquin & Fasolino, under review).
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The second manuscript (Chapter 3) is entitled “Renal Cell Cancer Syndromes:
Identification and Management of Patients and Families at Increased Risk” (Paquin & Fasolino
2020). There are many inherited renal cancer syndromes that increase an individual’s risk of
developing renal cell cancer (RCC). The major autosomal dominantly inherited RCC syndromes
include: von Hippel-Lindau syndrome (VHL); Lynch Syndrome/ Hereditary Non-Polyposis
Colorectal Cancer (HNPCC); Tuberous Sclerosis Complex (TSC); Birt-Hogg-Dubé Syndrome
(BHD); Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC); Cowden Syndrome; and
BAP1 Tumor Predisposition Syndrome. The age of onset for these RCC syndromes range from
infancy through 65 years. Clinical manifestations vary widely, and multiple body systems can be
involved and present unique challenges to the healthcare team. With the advancement of genetic
panels, clinicians can screen individuals with known hereditary syndromes for genetic mutations.
This paper presented clinically relevant information on specific to the major renal cancer
syndrome focusing on the gene mutation, incidence, and clinical implications (Paquin and
Fasolino 2020).
The third manuscript (Chapter 4) is entitled Comparison of Papillary Renal Cell
Carcinoma Type 1 and Type 2: A Secondary Data Analysis using The Cancer Genome Atlas”
(under review). This manuscript is a secondary data analysis using The Cancer Genome Atlas
Kidney Renal Papillary Cell Carcinoma (TCGA-KIRP) and cBioPortal data to determine if there
were significant differences between type 1 and type 2 PRCC tumors. Demographic, increased
risk factor and preferred genetic pathway data were determined for each PRCC tumor type.
Then a logistic regression was performed on each variable to determine the probability of that
variable being exhibited by type 2 PRCC tumors. This study found that higher age at diagnosis
was statistically more likely to be associated with type 2 tumors. Furthermore, type 2 tumors
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were found to prefer the PI3K pathway. Being African American had a negative association with
type 2 tumors. No increased risk factor variable was found to be significant, however further
research is needed to better understand how these variables can be used in determining tumor
subtype (Paquin et al., under review).
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Chapter II

Papillary Renal Cell Carcinoma: Epidemiology, subtype classification, and various genetic
pathways of the disease.
Overview
Papillary renal cell carcinoma (PRCC) is a subset of renal cell carcinoma (RCC). PRCC
is a heterogenous disease that consists of multiple subtypes, diverse genetic makeups, and a
continually changing epidemiology. Similarly, the management of PRCC reflects the complexity
of the disease. Clinicians should possess a basic knowledge of the subtype classification, genetic
pathways and epidemiology of PRCC in order to develop effective management plans.
Keywords: Papillary renal cell carcinoma, cancer treatment, cancer genetics
Introduction
Renal cell carcinoma (RCC) is the 14th most common cancer type worldwide with
approximately 430, 262 new cases and 175,098 deaths in 2018 (WHO, 2020). Papillary renal cell
carcinoma (PRCC) comprises 15-20% of all RCCs and is the second most common RCC
subtype. PRCC is largely considered a heterogenous disease given the histologically and
genetically distinct subtypes that vary in prognosis and disease progression. This heterogeneity
makes it difficult to diagnose and manage with approximately 20-50% of tumors being
discovered incidentally (Fernandes & Lopes 2015; Steffen et al. 2012). Mostly, PRCC is divided
into two subtypes, type 1 and type 2 (Pal et al. 2019). The aim of this paper is to provide the
clinician with an overview of PRCC inclusive of the epidemiology, subtype classification, and
various genetic pathways of the disease so that an appropriate management plan can be created.
Staging & Grading
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Typically, renal cancer is asymptomatic and any symptoms that occur are generally
attributed to other kidney diseases. Currently, 20-50% of PRCC tumors are discovered through
incidental findings (Fernandes & Lopes 2015; Steffen et al. 2012). Similarly, distinguishing
between type 1 and type 2 tumors can be difficult as well given the heterogeneity (Fernandes &
Lopes 2015; Modi and Singer 2015). Type 1 tumors are diagnosed at a younger age compared
with type 2 tumors. Additionally, type 2 tumors present with a poorer prognosis than type 1
tumors (Ahrens et al. 2019).
Tumor stage is a key prognostic parameter in cancer diagnosing. The most common
staging system is TNM where each tumor is given a letter and a number stage. In the TNM
system the T represents the size and extent of the main or primary tumor. Similarly, the N
represents the extent of lymph node involvement and lastly the M represents the extent of
metastasis. The letters representing the aforementioned TNM and the numbers range from 0
(cannot be found) to 3 or more (the higher the number the larger the tumor, the greater the
number of involved lymph nodes and the greater the metastasis). If there is an x after the letter
then the tumor cannot be found (National Cancer Institute, 2020; Table 1. TNM Staging
System). However, tumors can also be staged in five less descriptive categories. Stage I tumors
are confined to the kidney and less than 7.0 cm in size. Stage II tumors are also confined to the
kidney but are greater than 7.0 cm with no spread to lymph nodes or distant organs. Stage III
tumors have spread into the lymph nodes adjacent to the kidney or large vessels but no invasion
in adjacent organs or distant metastasis. Lastly, Stage IV tumors have invaded adjacent organs
and possibly distant metastases. spread to lymph nodes and possibly distant organs (National
Cancer Institute, 2020).
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The grading schema of RCC is based on the microscopic morphology of a neoplasm with
hematoxylin and eosin (H&E) staining. The most popular and used widely system for grading
RCC has been a nuclear grading system described in 1982 by Fuhrman et al (1982), which
concurrently evaluates nuclear size and shape, and nucleolar prominence. Grade one tumors have
round small nuclei (<10 micrometers) with small smooth nuclear contours and either absent or
inconspicuous nucleoli. Grade two tumors have slightly larger (15 micrometers) and irregular
nuclei with small not easily visible nucleoli. Grade three tumors have large (20 micrometers)
nuclei with prominent nucleoli (Cornejo et al. 2015). Lastly, grade four tumors have the largest
(> 20 micrometers) nuclei, with macro-nucleoli that have multi-lobation that exhibit
pleomorphism (Table 2. PRCC Fuhrman Nucleolar Grading System).
There are some criticisms of the Fuhrman Grading System, primarily the lack of
inclusion of recent subtypes of RCC. The grading system is designed so that each parameter will
increase in parallel and as each parameter increases, so will the tumor grade. However, studies
have shown that the importance of nuclear shape and tumor prognosis varies with RCC subtype.
Another limitation of the grading system is the lack of guidance as to which parameter should be
prioritized in variances (Delahunt et al. 2016). The initial results from the original study that
produced the Fuhrman Grading System have been difficult to replicate. Also, there is wide
variation among tumors within each tumor grade, further adding to the difficult reproducibility
(Delahunt el al. 2016). Considering there are no concrete alternatives, the Fuhrman Grading
System still remains the most widely used grading for RCC tumors.
Epidemiology of PRCC
The demographic variables associated with PRCC are under investigation. Therefore, the
risk factors and epidemiology associated with PRCC are umbrellaed under the more general
17

RCC. In general, RCC is twice as likely to occur in men than women. In fact, RCC is the 6th
most common cancer in men and 8th in women (Fernandes & Lopes 2015). The reasoning behind
the disparity is unclear but current theory attributes the increased likelihood to environment
exposures in the workplace. There are also a number of medical conditions that increase the risk
of renal cancer. Obesity, especially caused by a diet rich in fat, increases renal cancer risk. Other
conditions such as high blood pressure also may increase risk, although it is unclear if the
condition itself increases the risk or the medication (specifically diuretics). However, no specific
antihypertension drug has been linked to RCC, leading researchers to believe that hypertension is
the risk factor. However, it is unclear if RCC tumors are responsible for the development of high
blood pressure (Fernandes & Lopes 2015; Woldu et al. 2014).
More recent studies that have focused specifically on PRCC have shown that ethnicity
plays a role in the prognosis and treatment of PRCC with African Americans having poorer
survival rates compared to Caucasians (Paulucci et al. 2017). Similarly, given the genetic
heterogeneity of PRCC, a wide range of age groups are expected to be affected. Individuals with
hereditary papillary renal cell carcinoma generally develop PRCC type 1 tumors around the age
of 50 (Fernandes & Lopes 2015). Conversely, individuals with known Hereditary
Leiomyomatosis and Renal Cell Cancer (HLRCC), may develop PRCC type 1 tumors between
the age of 18 and 50, with an average age of 25 (Skala, Dhanaesekaran, & Mehra, 2018).
Furthermore, there is strong evidence that end stage renal disease (ESRD) is a strong risk factor
for developing PRCC. Studies have also shown that renal insufficiency, either chronic or
episodic renal failure, are corelated to an in increased risk of PRCC (Fernandes & Lopes 2015;
Woldu et al. 2014).
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There are a number of disorders that increase an individual’s risk of developing PRCC.
von Hippel-Lindau disease is the most common inherited disorder that is associated with renal
tumor development. Individuals with von Hippel-Lindau disease have a 40% risk of developing
renal tumors. von Hippel-Lindau disease is an inherited disorder characterized by the formation
of tumors and fluid-filled sacs (cysts) and VHL gene mutation. However, the loss of VHL
function is not sufficient to develop malignant tumors (Gupta et al. 2017; Gossage et al. 2013).
Likewise, HLRCC also known as Reed’s Disease, has been linked with the development of
PRCC type 2. HRLCC is an autosomal dominant condition in which individuals are at risk for
developing cutaneous leiomyomas, early onset multiple uterine leiomyomas, uterine fibroids and
PRCC type 2. The link between HRLCC and PRCC type 2 is found with fumarate hydratase
(FH) gene mutation. The FH gene codes for a critical Krebs cycle protein allowing the cell to
utilize oxygen to produce energy. FH mutation leads to cellular hypoxia which in turn leads to
tumor development (Skala, Dhanaesekaran, & Mehra, 2018).
Similarly, individuals with hereditary papillary renal cell carcinoma (HPRCC) disorder
have germline MET mutations and therefore have a higher risk for PRCC type 1 tumor
development. In fact, according to some estimates, individuals with HPRC have an almost 100%
risk of developing PRCC type 1. Although individual’s with HPRC have a greater risk of
developing PRCC, HPRC itself is a rare disorder (Haas and Nathanson, 2014). Interestingly,
individuals with a sibling who has a history of renal cancer (without having any of the previously
listed disorders) have a higher risk of developing renal cancer, including PRCC (Fernandes &
Lopes 2015).
Subtypes and Clear Cell Papillary Renal Cell Carcinoma
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An aspect of management is understanding the different subtypes associated with PRCC
given each subtype utilizes different diagnostic and treatment plans (Figure 1: Visual breakdown
of renal cell carcinoma subtypes). There are two main subtypes of PRCC, type 1 and type 2, and
are generally accepted as distinct enough to be defined given the heterogeneity. PRCC type 1
tumor morphology is seen in sporadic and hereditary forms of PRCC. PRCC type 1 tumors are
histologically characterized by having a single layer of small cells with sparse, basophilic
cytoplasm and small oval nuclei that cover renal papillae or tubules (Marsaud et al 2015;
Prochazkova et al. 2018).
In contrast, PRCC type 2 is generally more heterogenous and comprises less than a third
of PRCC cases (Marsaud et al 2015; Prochazkova et al. 2018). PRCC type 2 tumors are
histologically characterized by large pseudostratified cells that have a large spherical nucleus
with prominent nucleoli and eosinophilic cytoplasm that cover the renal papillae (Yin et al.
2015). If a tumor presents with a combination of type 1 and type 2 histological features, it would
be classified by the most predominant subtype. Similarly, if a tumor has an approximately equal
amount of type 1 and 2 features are classified as mixed (Sukov et al. 2011).
Recently, clear cell renal cell carcinoma (ccPRCC) has been recognized as a third
subtype of RCC. ccPRCC is histologically characterized by small to medium sized cuboidal cells
with ample cytoplasm that cover the renal papillae (Wang et al. 2020). ccPRCC shares similar
features with both PRCC and clear cell carcinoma but is distinct enough and does not fall under
either RCC subtype. For instance, ccPRCC tumors are surrounded by a fibrous capsule with both
papillary and clear cell morphology. Furthermore, ccPRCC tumors can appear to be densely
packed due to papillae branching (Morlote et al. 2019). ccPRCC is similar to PRCC in that
individuals are asymptomatic and tumors are found through incidental findings. Thus far
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ccPRCC can be found individuals of all ages with no race or age predilection. ccPRCC tumors
have favorable prognosis with low metastasis and reoccurrence rates. Similarly, if ccPRCC are
found early they may be managed with increased surveillance or minimal surgical means (Zhao
and Eyzaguirre, 2019). Although ccPRCC is not a subtype of PRCC, the name can be misleading
and it is important to recognize ccPRCC as distinct subtype of RCC.
Genetic Underpinning
In order to understand PRCC subtypes, an overview of the various genetic pathways
involved in tumor development is necessary. Given the heterogenous state of PRCC, a number of
genetic pathways exist and present as both sporadic (no inherited genetic changes) and hereditary
(inherited genetic changes) depending on the type of mutation exhibited in the tumor. Evidence
suggests that type 1 and type 2 tumors arise from a similar cytogenic pathway. Type 1 tumors
show significantly more gains in chromosomes 7p and 17p as compared to type 2 (Modi and
Singer 2015). Chromosomal gain or loss is significant in cancer cells because this allows for
tumor development by either gaining additional copies of oncogenes (tumor promoting) or losing
copies of tumor suppressor genes. Type 2 tumors are more genetically diverse compared to type
1 tumor and there are theories that type 2 tumors evolved from type 1 tumors after acquiring
more genetic mutations (Marsuad et al. 2015).
There are a number of genetic changes associated with PRCC type 1 tumors, either
sporadic or inherited. Approximately 20% of PRCC type 1 tumors are associated with mutations
of the protooncogene (a normal gene that when mutated becomes an oncogene) mesenchymal
transition factor (MET). The MET gene codes for the protein c-MET, which is a tyrosine kinase
receptor (RTK) protein. RTK proteins play a diverse role in the regulation of multiple cellular
processes including differentiation, proliferation and the regulation of the cell cycle (Albiges et
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al. 2014). Changes in MET generally allow for the continued growth and migration of cancerous
cells, which in turn increases tumor growth and invasion into healthy tissue. Hereditary PRCC
stems from a gain of chromosome 7, that contains a non-random mutated copy of the MET gene,
which results in the overexpression of the c-MET protein. Given that hereditary PRCC is rare,
familial non-random MET mutations are uncommon (Yin et al. 2015). Conversely, although
some studies suggest that MET mutations are found in approximately 13% of sporadic PRCC
type 1 tumors, it is believed that MET mutations do not play a major role in the development of
these tumors (Marsuad et al. 2016). Other studies have correlated gains of chromosome 17p with
type 1 tumors. There are several oncogenes that are located on chromosome 17p including
HER2, TOP2A and TAU. Additionally, 17p houses the tumor suppressor genes p53, BRCA1 and
HIC-1. The genes located on 17p have been linked to the initiation of tumor growth, tumor
progression, and tumor response to drug therapy. HER2 and TAU overexpression are correlated
with poor chemotherapy response and poor prognosis. TOP2A is involved with DNA replication
and TOP2A overexpression has been linked to tumor proliferation (Yu et al., 2013). Likewise,
p53 plays a critical role in tumor suppression and DNA repair, serving as a check point gene that
induces apoptosis when critical nonrepairable DNA errors are found. When p53 mutations occur,
DNA instability and unchecked cell proliferation occur. BRCA1 is similar to p53 in that it plays a
role in DNA regulation and repair. HIC-1 mutations are generally found in conjunction with p53
to inhibit apoptosis (Yu et al., 2013).
Type 2 tumors have been associated with a mutation in the tumor suppressor gene,
fumarate hydratase (FH). In healthy cells, FH acts as a catalyst for the conversion of fumarate
into malate during the Krebs cycle. PRCC type 2 FH mutations inactivate the FH protein causing
an accumulation of fumarate. The accumulation of fumarate then activates hypoxia inducible
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factor (and associated genes), which prompts the activation of other genes that increase tumor
cell survival and proliferation (Gardie et al. 2011). Additionally, mutations in the vascular
endothelial growth factor (VEGF) gene, specifically amplification, promote angiogenesis and
cellular migration. Furthermore, PRCC type 2 has been associated with a loss of chromosome 3
and 14. Chromosome 3 is the home for several tumor suppressor genes including, VHL which
plays a role in angiogenesis regulation. When VHL is suppressed hypoxia-inducible factor is
allowed to go unchecked which in turn leads to angiogenesis. Likewise, chromosome 14 houses
genes that are responsible for cellular regulation and apoptosis (Modi and Singer 2015: TCGA,
2016: Marsuad et al. 2015). Some studies have associated gains of chromosomes 7 and 17 with
type 2 tumors but to a lesser extent than type 1 (Yu et al., 2013).
Sporadic PRCC type 1 and type 2 share a number of genetic variations. For instance,
chromosome 17 gain has a high association with sporadic PRCC and is rarely found in non-renal
cancers (Marsuad et al. 2016). Specifically, a duplication of the 17q21 region, which contains the
oncogene HER2, was found to be associated with a large number of sporadic PRCC tumors
(Marsuad et al. 2016; Banumathy and Cairns, 2014). Allelic loss (loss of a specific gene
variation) has also been associated with sporadic PRCC tumor development, specifically loss of
the 7q31 region which contains the aphidicolin-inducible fragile site (FRA7G). The FRA7G site
contains the tumor suppressor genes, CAV1, CAV2 and TESTIN. Fragile sites such as FRA7G,
aid in tumorigenesis because they are easily susceptible to breakage, leading to chromosomal
translocation, deletion or amplification. Similarly, duplication of chromosome 20 and loss of
chromosome 9p are also common in sporadic PRCC tumors (Modi and Singer 2016; Marsuad et
al. 2016; Banumathy and Cairns 2014). Research is ongoing to determine what other genetic
factors play a role in PRCC tumor development.
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Management
There are a limited number of treatment options available for PRCC. Traditional
treatment therapies are targeted towards clear cell renal cell carcinoma and are generally
unsuccessful treating PRCC. Currently, nephrectomy is the most effective treatment option for
PRCC tumors regardless of tumor stage. Likewise, partial nephrectomy is the preferred treatment
choice since this option is nephron sparing and there are no after surgery treatment options
available (Dengina et al. 2017). Individual’s with advanced PRCC, characterized as stage 3 or
greater, are recommended to seek out clinical trials. Clinical trials are generally focused on
inhibiting specific cellular molecular pathways that are used by cancerous cells. Currently, the
m-TOR inhibitors, temsirolimus and everolimus, have proven more effective on non-clear cell
renal cell carcinomas (including but not limited to PRCC) as compared to interferon -α.
Similarly, smaller clinical trials with the VEGF inhibitor, sorafenib, has shown efficacy treating
PRCC. Efficacy was measured in progression free survival (PFS) and was shown to be 8.5
months for sorafenib as compared to 5.6 months for everolimus. Conversely, MET and EGFR
inhibitors, such as erlotinib, have not yet proven to be an effective treatment option for PRCC.
Current clinical trials do not differentiate between all the various types of non-clear cell
carcinomas and therefore no treatment can be specified for PRCC (Ahrens et al. 2019).
A new treatment option immune check point therapy, which has been shown to be
effective for clear cell carcinoma, is currently undergoing research for PRCC. Immune check
point therapy works to block proteins from binding with their receptors that would inhibit
immune cell activation. Thus, allowing the activation of immune cells such as T-cells to kill
cancerous cells. However, as of now, PRCC is treated the same as clear cell carcinoma or with
nephrectomy (Ahrens et al. 2019; Tsimafeyeu et al. 2017).
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Conclusion
PRCC is a complicated disease that consists of multiple subtypes and genetic pathways. It
is important for clinicians to have a basic understanding of PRCC in order to develop effective
personalized management plans. Furthermore, since PRCC remains difficult diagnose, clinicians
should be able to recognize at risk individuals. As research continues on PRCC, new
management techniques will be developed, having knowledge on the mechanism of the disease
will allow clinicians to provide the best individualized care possible.
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T (Tumor)

N (Lymph node

M (Metastasis)

involvement)
X

Cannot be measured

Cannot be measured

Cannot be measured.

0

Cannot be found

Cannot be found

Has not spread.

>1

Size and extent of

Number and location

Has spread to other

main tumor. A larger

of involved lymph

parts of the body.

number indicates

nodes. The higher the

greater size or

number, the more

infestation of

lymph nodes involved.

surrounding tissue.
Table 2.1. TNM Staging System (National Cancer Institute, 2020)
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Tumor Grade

Size and Shape of Nuclei

Tumor Size

Tumor Location

1

round small nuclei (<10

confined to the

less than 7

micrometers) with small smooth

kidney

centimeters across

slightly larger (15 micrometers)

confined to the

larger than 7

and irregular nuclei with small

kidney

centimeters across

large (20 micrometers) nuclei

surrounding

larger than 7

with prominent nucleoli

tissues or major

centimeters across

nuclear contours and either absent
or inconspicuous nucleoli
2

not easily visible nucleoli
3

veins but no
lymph nodes
4

largest (> 20 micrometers) nuclei,

lymph nodes

larger than 7

with macro-nucleoli that have

and possibly

centimeters across

multi-lobation that exhibit

distant organs

pleomorphism

Table 2.2. PRCC Furhman Fuhrman Nucleolar Grading System (Cornejo et al. 2015)
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PRCC

Whole

Whole

Common

Subtype

Chromosome

Chromosome

Gain

Loss

Type 1

7p, 17p, 20

9

Type 2

20

3,14,9

Allelic

Allelic

Loss

Gain

MET

7q31

17q21

FH, VEGF,

7q31

17q21

Associated
Oncogenes

HER2,
TOP2A, TAU,
p53, BRCA1,
HIC-1
Table 2.3. PRCC Genetic Variation Summary Table (Banumathy and Cairns, 2014Modi and
Singer 2015; Marsuad et al. 2015; Yin et al. 2015; Yu et al., 2013)
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Chapter III

Genetic Manifestations of Hereditary Renal Cancer: Identification and Management of
Patients and Families at Increased Risk

Melissa Paquin, PhD(c) mpaquin@clemson.edu
Tracy Fasolino, PhD, FNP-BC, ACHPN tfasoli@clmeson.edu

Overview: There are many inherited renal cancer syndromes that increase an individual’s risk of
developing renal cell cancer (RCC). The major autosomal dominantly inherited RCC syndromes
include: von Hippel-Lindau syndrome (VHL); Lynch Syndrome/ Hereditary Non-Polyposis
Colorectal Cancer (HNPCC); Tuberous Sclerosis Complex (TSC); Birt-Hogg-Dubé Syndrome
(BHD); Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC); Cowden Syndrome; and
BAP1 Tumor Predisposition Syndrome. The age of onset for these RCC syndromes range from
infancy through 65 years. Clinical manifestations vary widely, and multiple body systems can be
involved and present unique challenges to the healthcare team. With the advancement of genetic
panels, clinicians can screen individuals with known hereditary syndromes for genetic mutations.
This paper will present clinically relevant information on specific to the major renal cancer
syndrome focusing on the gene mutation, incidence, and clinical implications.
Key Words: Hereditary renal cancer syndromes; autosomal dominant; renal cell cancer; gene
mutation
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Introduction
Individuals with inherited renal cancer syndromes develop kidney cancer at an earlier age
with notable features of heterogeneous, multifocal, and bilateral tumors. Several of the
syndromes have renal cell cancer (RCC) as a primary feature, including von Hippel-Lindau and
Birt-Hogg-Dubé syndrome, whereas others, such as Lynch syndrome and Cowden syndrome,
have RCC as a secondary feature. Most hereditary renal cancer syndromes are autosomal
dominant, meaning that only one copy of the mutated gene is needed to present to express the
disease. The mutated gene predisposes affected individuals to tumor development often with
early onset malignancy (da Costa et al. 2017). Children of parents with autosomal dominant
diseases have a 50% chance of inheriting the syndrome. Each hereditary renal cancer syndrome
manifests with different clinical symptoms and is correlated with varying risks of developing
RCC. This paper will present clinically relevant information of hereditary renal cancer
syndromes associated with RCC with a focus on the incidence, background and clinical
implications (Table 1).
Von Hippel-Lindau Syndrome
Von Hippel-Lindau (VHL) syndrome, is the most common hereditary renal syndrome. It
is characterized by visceral cysts and benign tumors that have the potential to become malignant.
In fact, individuals with VHL have a 40% chance of developing RCC (Gupta et al. 2017).
However, the loss of VHL gene function alone is not enough for patients to develop RCC. Other
gene mutations in conjunction with VHL, including BAP1, PBRM1, JARID1c, SETD2, and
KDM6A, have been found in patients with RCC, indicating that multiple gene mutations are
involved with RCC development (Gossage et al. 2013). More recently, SDHB and TMEM127
alterations have been linked to VHL mutations but their connection to RCC is unclear. (Gupta et
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al. 2017). Further research is necessary to determine the exact relationship between SDHB,
TMEM127, VHL and RCC.
Lynch Syndrome (LS)/Hereditary non-polyposis colorectal cancer (HNPCC)
LS, synonymous with HNPCC, is a condition that predisposes individuals to increased
risk of colorectal cancer (CRC), endometrial cancer, upper tract urothelial cancers, and other
types of cancers. (Lynch et al. 2015). A number of germline mutations are associated with LS,
specifically in the mismatch repair genes (MMR). These genes are responsible for correcting
mismatched nucleotides when DNA is copied in preparation for cell division. Germline
mutations in the MSH2, MSH6, MLH1 and PMS2 genes (members of the MMR gene family) are
the most common cause of LS (Ziada-Bouchaar et al. 2017). Furthermore, deletions in the
EPCAM gene, a gene that codes for a cell adhesion protein, can result in silencing of the MSH2
gene, which can lead to EPCAM-associated Lynch Syndrome.
Tuberous Sclerosis Complex (TSC)
TSC is a rare, multisystem disease characterized by multiple benign tumors found in the
brain, spinal cord, kidneys, heart, and other areas due to mutation in the tumor suppression
genes, TSC1 or TSC2. Each of these genes code for proteins involved in cell proliferation.
Typically, individual’s with TSC present with benign renal tumors (Leech et al. 2018). However,
when both copies of the gene are mutated, an individual has a greater chance of developing
malignant renal tumors
Birt-Hogg-Dube Syndrome (BHD)
BHD syndrome is an extremely rare complex disorder characterized by deletion of the
folliculin gene (FCLN) (Centini et al. 2018). The FLCN gene transports instructions to produce
folliculin, a protein whose precise function is not known but seems to interact with proteins
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involved in cell growth, energy production, and metabolism. As a tumor suppressor gene, FLCN
gene aids in apoptosis but mutations predispose individuals to cancer development
Hereditary Leiomyomatosis Renal Cell Carcinoma (HLRCC)
HLRCC, otherwise known as Reed’s syndrome, is a syndrome characterized by the
presence of one or more of the following: cutaneous leiomyomas (average age of occurrence is
25), uterine leiomyomas/fibroids (average age of occurrence is 30), and renal cell cancer (RCC)
(National Cancer Institute, 2019). The pattern of renal cancer in HLRCC differs from other
inherited renal cancer syndromes in that the tumors tend to be solid, unilateral, and more
aggressive (Skala, Dhanaesekaran, & Mehra, 2018). HRLCC is caused by a germline mutation in
the FH gene, which codes for an enzyme that catalyzes the conversion of fumarate into L-malate
during the Krebs Cycle (Valencia et al. 2017). Fumarase, or fumarate hydratase, allows the cells
to use oxygen and generate energy. Excesses of fumarate may interfere with cellular oxygen
levels, yielding chronic hypoxia leading to tumor formation and tendency to develop
leiomyomas and RCC.
Cowden Syndrome
Cowden Syndrome (CS) is a relatively rare condition that predisposes individuals to
developing renal tumors and is characterized by multiple, noncancerous growths (called
hamartomas) at various sites of the body. Nearly all patients with CS will present with benign
growths on the skin, mouth and along the inner lining of the gastrointestinal tract by the end of
their 20s (Eng, 2016). Mutations in four different genes, PTEN, SDHB, SDHD, and KLLN, have
been identified in people with CS. Of interest is the tumor suppressor gene, PTEN, which codes
for a protein involved in cell proliferation (Breuksch et al. 2018). Additionally, SDHB-B and
KLLN have been found to contribute to CS even in the absence of a PTEN mutation. However,
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individuals with a KLLN mutation have a higher risk of developing RCC as compared to
individuals with a SDHB-B mutation. Currently, testing for the KLLN mutation is not readily
available (Mahdi et al. 2015).
Implications for Nurses
Hereditary renal cancer syndromes account for approximately 5% of all kidney cancers,
though this number is probably underestimated (Kallinikas et al, 2017). The number of families
identified with hereditary conditions leading to RCC continues to increase as germline genetic
testing is being utilized more frequently. As presented, RCC can either be a major or a minor
feature of the cancer susceptibility syndrome. However, RCC is not limited to hereditary renal
cancer syndromes or the gene mutation discussions. In fact, mutations in the MET, MITF, and
SDH genes also have a strong association with an increased risk of RCC.
Early age of onset, unusual or pathognomonic pathology, and multiple tumors in a patient
with renal cancer raises concern for hereditary renal cancer syndromes. Accurate, ongoing, and
complete assessment of family history is the first step in identifying individuals who may be at
risk for hereditary renal cancer syndromes. Nurses need to inquire about the type of kidney
cancer as well as the presence of other indicators of hereditary risk particularly dermatologic and
other unusual findings. Families with unusual histories should be referred for further evaluation
and possible genetic testing to credentialed genetics professional.
The identification of known mutation carriers enables the implementation of aggressive
and often complex surveillance in those likely to benefit and prevents unnecessary aggressive
surveillance in those who do not have an inherited risk. The complexity of screening for those
with hereditary risk requires regular coordination. Surveillance and prevention recommendations
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should be reviewed annually by genetics professional to verify that they are still current and
evidence based.
Known carriers may have concerns and dilemmas about reproduction and the possibility
of passing a mutation to offspring. These individuals often require ongoing psychosocial support
to manage the consequences of their genetic predisposition. Oncology nurses can offer support to
these individuals and families and refer them to resources (see Figure 1).
Conclusion
Management of individuals with hereditary polyposis syndromes demands accurate
assessment of patients’ personal and family history, referral for genetic evaluation and testing,
and implementation of complex surveillance plans to ultimately decrease the morbidity and
mortality associated with these syndromes. Oncology nurses play an integral role in supporting
these patients and families as they manage the complexities of their diagnoses and ongoing care.
Nursing Implications
1. Renal cell cancer syndromes are autosomal dominant and increase an individual’s risk of
developing renal cell cancer and other malignancies.
2. The age of onset for renal cell cancer ranges from infancy through 65 years with a wide
range of clinical manifestations that include benign and malignant histology.
3. Heightened surveillance and pre-emptive management of individuals with known renal
cell cancer syndromes can improve outcomes and quality of life.
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Figure 3.1
Resources for Hereditary Cancer Syndromes
General Resources
•
•

Kidney Cancer Association www.kidneycancer.org
National Cancer Institute – Genetics of Kidney cancer
https://www.cancer.gov/types/kidney/hp/kidney-genetics-pdq#_362_toc

Birt Hogg Dube
•
•
•
•

National Library of Medicine Genetics Home
Reference https://ghr.nlm.nih.gov/condition/birt-hogg-dube-syndrome
Genetic and Rare Disease Center https://rarediseases.info.nih.gov/diseases/2322/birthogg-dube-syndrome
Gene Reviews: https://www.ncbi.nlm.nih.gov/books/NBK1522/
BHD Foundation: https://www.bhdsyndrome.org/

Von Hippel Lindau
•
•
•

•
•

National Library of Medicine Genetics Home Reference
https://ghr.nlm.nih.gov/condition/von-hippel-lindau-syndrome
Genetic and Rare Disease Center: https://rarediseases.info.nih.gov/diseases/7855/vonhippel-lindau-disease
National Institute of Neurological Diseases and Stroke
https://www.ninds.nih.gov/Disorders/All-Disorders/Von-Hippel-Lindau-Disease-VHLInformation-Page
Gene Reviews https://www.ncbi.nlm.nih.gov/books/NBK1463/
VHL Alliance: https://www.vhl.org/

Lynch Sydrome
•
•
•
•

National Library of Medicine Genetics Home Reference
https://ghr.nlm.nih.gov/condition/lynch-syndrome
Genetic and Rare Disease Center https://rarediseases.info.nih.gov/diseases/9905/lynchsyndrome
Gene Reviews https://www.ncbi.nlm.nih.gov/books/NBK1211/
Lynch Syndrome International: https://lynchcancers.com/

Tuberous Sclerosis Complex
•
•
•

National Library of Medicine Genetics Home Reference
https://ghr.nlm.nih.gov/condition/tuberous-sclerosis-complex
Genetic and Rare Disease Center:
https://rarediseases.info.nih.gov/diseases/7830/tuberous-sclerosis
Gene Reviews https://www.ncbi.nlm.nih.gov/books/NBK1220/
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•

Tubular Sclerosis Complex https://www.tsalliance.org/

Hereditary Leiomyomatosis Renal Cell Carcinoma
•
•

•

National Library of Medicine Genetics Home Reference
https://ghr.nlm.nih.gov/condition/hereditary-leiomyomatosis-and-renal-cell-cancer
Genetic and Rare Disease Center:
https://rarediseases.info.nih.gov/diseases/10096/hereditary-leiomyomatosis-and-renalcell-cancer
HLRCC Family Alliance http://hlrccinfo.org/

Cowden Syndrome
•
•
•

National Library of Medicine Genetics Home Reference
https://ghr.nlm.nih.gov/condition/cowden-syndrome
Genetic and Rare Disease Center
https://rarediseases.info.nih.gov/diseases/6202/cowden-syndrome
Gene Reviews: https://www.ncbi.nlm.nih.gov/books/NBK1488/

BAP1 Tumor Predisposition Syndrome
•
•

National Library of Medicine Genetics Home Reference
https://ghr.nlm.nih.gov/condition/bap1-tumor-predisposition-syndrome
Genetic and Rare Disease Center https://rarediseases.info.nih.gov/diseases/13219/bap1tumor-predisposition-syndrome
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Table 3.1. Summary of Hereditary Renal Cancer Syndromes.

Hereditary
Syndrome
von HippelLindau (VHL)

Lynch
Syndrome/
Hereditary nonpolyposis
colorectal
cancer
(HNPCC)

Incidence
1 in 36,000
people (10,000
cases in the
US and
200,000 cases
worldwide),
Males and
females
equally
affected

Estimated
frequency is
1:370 to
1:2000.
Approximately
140,000 new
cases of colon
cancer yearly
in the US; 35% of these
caused by
Lynch
Syndrome

Average
Age of
Onset
Mean age
of onset is
26 years
with most
patients
presenting
with
symptoms
by 65

Clinical Manifestations

Genes

Screening Surveillance

Hemangioblastomas of the eye,
brain and spinal cord

VHL

Yearly physical and eye
exams to monitor for small
asymptomatic lesions as well
as detect new early stage
lesions.

Pheochromocytomas
Endolymphatic sac tumors

24-hour urine test for elevated
catecholamines beginning at
age 5

RCC

abdominal ultrasound (teen
years) or magnetic resonance
imaging (adulthood) to assess
the kidney, pancreas, and
adrenal glands.
Mean age
of onset is
40 years

Early onset colon cancer
Endometrial cancer
Ovarian cancer

MSH2,
MSH6,
MLH1,
PMS2,
EPCAM

Sebaceous adenomas

Colonoscopy every 12 to 24
months starting at age 20 to
25 or two to five years before
the youngest diagnosis of
colon cancer in the family
Risk reducing hysterectomy
with bilateral
salpingoophorectomy when
childbearing is complete

Pancreatic cancer
RCC

Esophagogastroduodenoscopy
every 3 to 5 years starting at
age 30. Treatment of H
pylori infections
Annual urinalysis starting at
age 30
Consider pancreatic screening

Tuberous
Sclerosis
Complex (TSC)

25,000 to
40,000
individuals in
the US and
nearly 1
million
worldwide

Infancy

Numerous benign growths
Developmental delay
Seizures
Lymphangioleiomyomatosis (LAM)
Polycystic kidney disease
RCC

TSC1,
TSC2,

Evaluate for seizures. Obtain
routine EEG in individuals
with known or suspected
seizure activity. The
frequency of routine EEG
should be determined by
clinical need.
Imaging for benign growths,
and psychiatric evaluation
beginning in childhood.
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Obtain MRI of the brain
every one to three years in
asymptomatic persons by age
25
MRI of abdomen to assess for
angiomyolipoma & renal
cysts by age 25 every 1 to 3
years
Assess renal function
(including determination of
GFR) and blood pressure at
least annually by age 25.
Perform clinical screening
(targeted history) for LAM
symptoms including
exertional dyspnea and
shortness of breath at each
clinic visit for women older
than age 18 years or those
who report respiratory
symptoms. Counseling
regarding smoking risk and
estrogen use should be
reviewed at each clinic visit
for individuals at risk for
LAM.

Birt-HoggDube Syndrome
(BHD)

200 and 600
families
worldwide

Unknown

FCLN

Lung cysts
Benign skin tumors:
Fibrofolliculomas, Trichodiscomas,
Angiofibromas, Acrochordons and
Perifollicular fibromas
Spontaneous pneumothorax
Renal tumors including hybrid
oncocytic renal cell carcinoma,
oncocytoma, chromophobe renal cell
carcinoma, and clear cell renal cell
carcinoma

Perform detailed clinical
dermatologic inspection/exam
annually.
Renal imaging is appropriate
for individuals age 18 years
or older. Yearly MRI of the
kidneys is the optimal
screening modality to assess
for kidney lesions.
Abdominal/pelvic CT scan
with contrast is an alternative
when MRI is not an option.
However, the long-term
effects of cumulative
radiation exposure in
individuals with BHDS is
unknown and has not been
studied.
Annual full body skin
examination
Avoid
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-Cigarette smoking
-High ambient pressures,
which may precipitate
spontaneous pneumothorax
-Radiation exposure

Hereditary
Leiomyomatosis
Renal Cell
Carcinoma
(HLRCC)

Unknown

25-30
years of
age

Cutaneous leiomyomas
Uterine leiomyomas (fibroids)
Kidney cancer

FH

Annual full body
dermatologic examination
Annual gynecologic
consultation is recommended
to assess severity of uterine
fibroids and to evaluate for
changes suggestive of
leiomyosarcoma.
Yearly examination with
abdominal MRI is
recommended for individuals
with normal initial baseline or
follow-up abdominal MRI.
MRI is preferred because of
the potential added radiation
exposure associated with CT
over lifetime.

Cowden
Syndrome

Unknown

Late 20s

Hamartomas (benign growths) on
the skin, mouth and gastrointestinal
tract.
Macrocephaly
Trichilemmomas and papillomatous
papules
Benign breast, thyroid and
endometrial diseases.
Kidney cancer and congenital
kidney anomalies
Lhermite -Dulcos Disease, autism
spectrum disorder, intellectual
disabilities and vascular
abnormalities.
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PTEN

Children (age <18 years).
Yearly thyroid ultrasound
from the time of diagnosis
and skin check with physical
examination.
Adults. Yearly thyroid
ultrasound and dermatologic
evaluation.
Women beginning at age 30
years. Monthly breast selfexamination; annual breast
screening (at minimum
mammogram; MRI may also
be incorporated) and
transvaginal ultrasound or
endometrial biopsy.
Colonoscopy beginning at age
35 years with frequency
dependent on degree of

polyposis identified; biennial
(every 2 years)
Renal imaging (CT or MRI
preferred) beginning at age 40
years.
Those with a family history of
a particular cancer type at an
early age. Consider initiating
screening 5-10 years prior to
the youngest age of diagnosis
in the family.
BAP1 Tumor
Predisposition
Syndrome

Unknown

20s

Mesothelioma
Uveal melanoma.
Atypical Spitz tumors
Melanoma
Clear cell kidney carcinoma
Basal cell skin cancer
Cholangiocarcinoma

BAP1

Yearly dilated eye
examinations and imaging by
an ocular oncologist
beginning around age 11
years for uveal melanoma
Annual evaluation is
recommended for late
manifestations of
mesothelioma, which can
include chest pain, cough,
fever, shortness of breath,
dysphagia, hoarseness, weight
loss, fever, upper body and
face edema (chest
mesothelioma) and abdominal
pain, ascites, nausea,
vomiting, and/or constipation
(peritoneal mesothelioma).
Annual physical examination
is recommended to look for
signs of pleurisy (pleural
inflammation), peritonitis,
ascites and/or pleural
effusion.
Annual full body
dermatologic examinations
beginning around age 20
years
Annual abdominal ultrasound
examination; consideration of
annual urinalysis and
abdominal MRI every two
years to monitor for renal
cancer

Based on information from (Colorectal Cancer Alliance, 2019; Gupta et al. 2017; Therkildsen et al. 2016; National
Comprehensive Cancer Network, 2019; National Institute of Neurological Disorders & Stroke, 2019; Menko et al
2017; Masoomian et al. 2018; National Institute of Neurological Disorders and Stroke, 2019 a,b,c,d
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Chapter IV
Background
Renal cell carcinoma (RCC) is the 14th most common cancer worldwide and was the
cause of 175,098 deaths in 2018 (WHO, 2020). RCC consists of numerous subtypes including
clear cell renal carcinoma, papillary renal cell carcinoma and most recently clear cell papillary
renal cell carcinoma. Currently, papillary renal cell carcinoma (PRCC) is the second most
common type of RCC, after clear cell renal cell carcinoma, comprising approximately 15-20% of
all RCC cases (Fernandes & Lopes 2015; Steffen et al. 2012). PRCC is considered to be a
heterogeneous disease that consists of two subtypes; type 1 and type 2. PRCC subtypes are
primarily distinguished by their histology and vary in prognosis, treatment and patient outcomes.
Type 1 is histologically characterized by a single layer of cells with sparse basophilic cytoplasm
and small oval shaped nuclei that are present in either the renal tubules or renal papillae. Type 1
tumors can be associated with both hereditary and sporadic PRCC (Marsaud et al 2015;
Prochazkova et al. 2018). Conversely, type 2 tumors are histologically characterized by large
pseudostratified cells with eosinophilic cytoplasm with large spherically shaped nuclei that are
present in the renal papillae. Type 2 tumors can be associated with hereditary PRCC but are
more often associated with the sporadic form of PRCC (Yin et al. 2015). Furthermore, research
has shown that patients with PRCC type 2 tumors are correlated with a higher rate of metastasis
and have a lower overall survival rate compared with patients with type 1 tumors (Wong et al.
2019).
Research has shown that malignant tumors utilize a wide variety of genetic alterations to
modify the normal cell cycle in order to be able to divide and grow without restrictions. These
modifications are accomplished by altering cell signaling pathways to promote cell growth,
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angiogenesis and obstruct apoptosis (Sanchez-Vega et al. 2018). Considering the heterogeneous
nature of PRCC, there are numerous genetic alterations that occur within both type 1 and type 2
PRCC. Approximately 20% of hereditary type 1 tumors have been associated with variations in
the protooncogene mesenchymal epithelial transition (MET). However, sporadic type 1 tumors
have numerous genes associations as well as chromosomal abnormalities. Type 2 tumors have
also been correlated with a large number of genetic and chromosomal alterations (Marsuad et al.
2016; Linehan et al. 2015). Similarly, research has shown that renal cancers in general utilize
several signaling pathways. The alteration of MET has been shown to activate the MAPK and
PI3K pathways as well as other proteins involved with tumor growth (COJOCARU et al. 2015).
However, research still needs to be done to determine if there is a preference of pathways
specific to type 1 or type 2 PRCC tumors.
The epidemiology and risk factors for PRCC are largely based on the broader RCC.
However, there are certain conditions that may increase an individual’s risk of developing
PRCC. For instances individuals with Hereditary Leiomyomatosis and Renal Cell Cancer
(HLRCC) have a greater chance of developing PRCC type 1. Furthermore, there is some
evidence that suggests individuals with renal insufficiencies have a greater risk of developing
PRCC (Paquin & Fasolino 2020; Fernandes & Lopes 2015; Woldu et al. 2014). Ethnicity has
also been found to contribute to the risk of developing an RCC with African Americans having
the highest incidence of RCCs in the United States. Sankin et al. (2011) found that African
Americans had a four times greater incidence of PRCC as compared to non-African Americans
(Hsieh et al. 2017; Sankin et al. 2011). However, research is still needed to further understand
the risk factors specific to PRCC. Currently there are limited treatment options available for both
types of PRCC. Presently, the standard treatment is partial or full nephrectomy. Individual’s with
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higher grade tumors are encouraged to seek out clinical trials, which tend to be developed based
on specific cellular molecular pathways. Similarly, the prognosis of PRCC is dependent on
tumor type (Dengina et al. 2017; Ahrens et al. 2019).
Most research on PRCC has either been umbrellaed under RCC or has been focused on
developing a basic understanding of the disease. Furthermore, there is limited research focusing
on the differences between type 1 and type 2 PRCC tumors. Given the findings in Wong et al.
(2019) with respect to survival rates associated with type 1 and type 2 PRCC and the fact that the
data we collected contained overall (presumably, all-cause mortality survival times) as well as
demographic, environmental as well as gene pathway information our research plan is four-fold.
First, we will analyze the all-cause mortality investigate whether we see discrepancies in survival
rates between type 1 and 2 PRCC. The second phase will consist of selecting a demographic
(baseline) model which will identify a set of demographic variables that are likely to be
associated with the two different types of PRCC. In the third and fourth phases we will
investigate environmental and gene pathway associations with prevalence of the two types of
PRCC. The overall aim of these analyses is to determine if there are significant differences
between type 1 and type 2 PRCC that can be utilized by healthcare providers. Specifically, this
study sought to determine if there are clinically significant differences in survival, demographics
(age, ethnicity, gender, and race), increased risk factors (body mass index [BMI] smoking
history, neoplasm history, and malignancy history) and preferential genetic pathways between
type 1 and type 2 PRCC tumors.
Methods
Sample
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This study was a secondary data analysis using data from The Cancer Genome Atlas
Kidney Renal Papillary Cell Carcinoma (TCGA-KIRP). A review of the literature was conducted
to determine the appropriate inclusion criteria which were: 1) PRCC tumors, 2) distinguishes
between type 1 and type 2, 3) demographics data ,gender, race, age and ethnicity, 4) clinical data,
prognosis, treatment, preexisting conditions, 5) increased risk factors, smoking history, BMI,
prior neoplasms and prior malignancies and 6) genetic analysis of the tumors. A further review
of the literature revealed that TCGA-KIRP is the most current and appropriate dataset to use for
this secondary data analysis. The cBioPortal for cancer genomics (cBioPortal) was also used to
analyze the TCGA-KIRP data.
TCGA- Kidney Renal Papillary Cell Carcinoma (KIRP) data was collected from 41
institutions from 1996 to 2013. TCGA adheres to a strict inclusion policy for data to be included
on the website. TCGA tumors are untreated samples that were snap frozen. Each tumor sample
has to have a matched normal sample from the same patient which generally comes in the form
of the patient’s blood. The tumors and subsequent molecular data are cross referenced by
Biospecimen Core Resource (BCR) to ensure validity. Furthermore, the BCR analyzes each
sample for pathological quality control. This maintains that TCGA has a high-quality tumor
samples as well as consistent molecular data (TCGA, 2020). Additionally, each sample was
reviewed by a panel of six experienced pathologist to in order to be classified into type 1, type 2
or unclassified PRCC. Moreover, any samples that were pre-classified were reassessed by the
same panel to ensure proper classification (TCGA, 2020).
The cBioPortal is a resource that incorporates data from TCGA and other reliable
sources, when possible, into a more researcher-friendly resource. The BCR provides an
interactive resource that can be used for a more comprehensive secondary data analysis. For
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example, the cBioPortal separates PRCC genetic variations into categories such as copy number
variations and mutations. Furthermore, the cBioPortal predetermines and denotes driver genes
through specific algorithms. Additionally, the cBioPortal allows the user to analyze specific
genes as opposed to TCGA which only allows users to view the dataset as a whole and does not
denote potential driver genes. Even though the cBioPortal contains the same data as TCGA, the
cBioPortal was used to aid in the analysis of TCGA data.
Data Extraction
A total of 292 cases were available on the listed datasets. The first step in evaluating the
dataset was determining the clinical and demographic data. TCGA contains a manifest that
includes all relevant clinical, demographic and environmental data. This manifest was
downloaded and converted into an Excel file. Once retrieved the dataset was combed and
irrelevant data was eliminated from the dataset. Irrelevant data included data categories with n/a,
data categories on serum levels, blood cell counts, etc. Data categories that were redundant were
also eliminated.
Next, the cBioPortal resource was used to determine pertinent genetic information related
to PRCC. The first step was to download the copy number alteration (CNA) data from the
cBioPortal website. A total of 10,837 genes exhibited a copy number variation. Genes that were
not considered to be driver genes according to the GISTIC algorithm were eliminated from the
dataset. This elimination left a total of 426 driver genes with CNA. The driver genes were then
put into the BCG query to determine how many cases included one or more of the driver CNA
genes. It was found that 193 of the cases or 66% contained one of the driver CNA genes. In order
to increase the sample population, mutated driver genes (as determined by Mutsig) were added to
the query bringing the total of genes up to 517. This addition brought the number of cases to 255
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or 87% of the dataset. 36 cases did not have an association with one of the 517 driver genes and
were therefore eliminated for continuity of the data. The driver genes were also divided into
categories based on their cytoband for future reference.
Subsequently, the remaining 255 cases were reviewed to determine whether or not they
were designated type 1 or type 2 PRCC. Out of the 255 cases, 115 cases had an NA designation
in the type category. The pathology report of each of the 115 cases was reviewed to see if a
pathologist had designated the tumor as either type 1 or type 2. At the conclusion of this analysis
88 cases were type 2, 69 cases were type 1 and 83 cases remained NA. The 83 NA cases were
subsequently removed from the dataset in order to preserve the validity and continuity of the
data. Furthermore, seven cases were determined to be a mix of type 1 and type 2 histology and
were also removed. Additionally, eight more cases were determined to favor a different cancer
type per the reviewing pathologist. These eight cases did not include a TCGA addendum that
disputed the cancer typing and therefore were removed from this dataset. (See Figure 1)
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Fig. 1 Consort diagram describing TCGA-KIRP data extraction.

Analysis
Descriptive Statistics and Survival Analysis
First descriptive statistics were determined using excel for each of the domains;
demographics, increased risk factors and genetic pathways. Then a survival analysis was
conducted for the TCGA-KIRP analytic file using R version 3.6.2. A cox-proportional hazard
model was fitted on the overall survival times of 156 patients (1 had a survival time of 0
indicating that they were diagnosed post-mortem or there was an error in entry) to determine if
there were evidence that survival rates differ between Type 1 and 2 PRCC.
Logic Regression
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For the next three phases of our investigation statistical analysis for this data was
performed using SAS program software package for Windows. The demographic model
selection included age at diagnosis, race, ethnicity and sex, as candidate descriptors relating to
PRCC tumor type. The demographic model selection utilized forward selection with a relaxed p
value (<0.1) to determine the appropriate variables to be included in the model. The selected
demographic model included Age at Diagnosis (OR 1.045 95% CI 1.014, 1.078 Table 5) as well
as 3 Category Race (which was not significant at the .1 level when included in the final candidate
model but had a sufficient p-value to be selected for inclusion) was used as the baseline model
for the increased risk factor variables. Each increased risk factor variable, BMI, smoking status,
prior neoplasms and prior malignancies, were added univariately to the demographic model
controlling for age at diagnosis and race to identify associations.
Results
Descriptive Statistics
Of the 69 type 1 tumors, 50 were male and 19 were female with a median age of 60
(range 28 to 82). In terms of race 46 were white, 18 were black or African American, 5 were
unspecified and for ethnicity 62 were non-Hispanic or Latino, 2 were Hispanic or Latino and 5
were unspecified. Of the 88 type 2, 61 were male and 27 were female with a median age of 65
(range 28 to 88). In terms of race 66 were white, 15 were black or African American, 7 were
unspecified and for ethnicity 75 were non-Hispanic or Latino, 5 were Hispanic or Latino and 8
were unspecified (Table 1). Due to the sparsity in the demographic factor levels the following
variable levels were collapsed; Asian and American Indian. Smoking categories were defined as
life-long non-smoker (1), current smoker (2), reformed smoker >15years (3), reformed smoker
<15 years (4) and reformed smoker unknown length (5). For type 1 tumors 30 were category 1,
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10 were category 2, 10 were category 3, 7 were either category 4 or 5 smokers and 11 were
unspecified. For type 2 PRCC tumors 36 were category 1, 11 were category 2, 14 were category
3, 20 were category 4 or 5 and 7 were unspecified. Once again due to sparsity in the increased
risk factor levels the following variables were collapsed; smoking category 4 and 5. Prior
neoplasms were defined as either yes or no with 2 yes in type 1 and 9 in type 2. Similarly, prior
malignancies were also defined as either yes or no with 16 yes in type 1 and 14 in type 2 (Figure
2). Lastly the most common pathway in type 1 was the MAPK pathway and in type 2 was the
PI3K pathway Figure 3).
Overall Survival
The hazard ratio (comparing Type 2 to 1, with Type one being the reference group) was
2.459 (with 95% CI 0.9723, 6.217) which does not provide sufficient evidence at the 𝛼 =
.05 level that the two types differ significantly in all-cause survival. However, given the
relatively small sample size and high rate of censoring (70.3% for Type 1 and 52% for Type 2,
which consequently prevents us from being able to report median survival without making
parametric assumptions) it is not surprising that our results do not provide as striking a contrast
between the two as was found in Wong et al. (2019). Survival rates are illustrated via the Kaplan
Meier curve included in Figure 2.
Logistic Regression
Odd ratios (OR) and confidence intervals (CI) are reported in Tables 5 and 6 for each
variable in the increased risk factor and pathway analyses. Out of the increased risk factor
variables investigated we found that smoking appeared to be associated with increased risk of
Type 2. Specifically, being a reformed smoker of unknown length or less than 15 years (these
two categories were grouped together due to sparsity) was positively associated with Type 2
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PRCC compared to life-long non-smokers (OR 3.241 95% CI 1.066, 9.853 Table 5). None of the
other increased risk factors had a significant association with tumor type. In the pathways
analysis we observed one significant association and that was a significant difference between
MAPK and PI3K with PI3K being significantly associated with Type 2 (OR 4.968 95% CI
1.759, 14.031 Table 6). In all analyses Type 1 was used as the reference level for each model
and the OR correspond to odds of Type 2 vs 1.
Discussion
To the best of our knowledge our study is the first to collectively examine the
demographic, increased risk and pathway associations between type 1 and type 2 PRCC tumors.
Furthermore, while our findings with respect to the survival analysis were not significant at the
𝛼 = .05 level (in our setting p=.0573), it does provide marginal evidence to confirm the findings
of Wong et al. (2019) in that survival rates for Type 2 are on average shorter than those for Type
1. Our secondary data analysis was limited to a small population sample with a lot of
missingness among the dataset. None the less, our study certain variables were found to have an
increased probability of being associated with type 2 PRCC tumors. The first variable found to
be significant was age at diagnosis with an increase in age at diagnosis being indicative of an
increased risk of type 2. This finding is supported by the fact that 20% of type 1 tumors have an
association with a germline MET mutation and literature has shown that having a germline
mutation is positively associated with a younger diagnosis age (Lineman et al. 2015). Although
there are germline mutations associated with type 2 PRCC tumors, they are less prominent than
type 1 (Lineman et al. 2015; Hsieh et al. 2018).
Smoking was the only increased risk factor that was significant in determining the
probability of having the type 2 tumor type. Individuals who were reformed smokers of less than
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15 years (as well as reformed smokers of unknown length) had a greater risk of developing a
type 2 tumor as compared to lifelong non-smokers. Furthermore, type 2 PRCC tumors tend to be
sporadic as compared to type 1, meaning that increased risk factors may have a greater impact on
the development of type 2 tumors (Yin et al. 2015). However, further research needs to be
conducted on the effects of smoking on the growth of specific tumor subtypes. Additionally, the
increased risk factor dataset had a large amount of missingness with prior neoplasm having the
most missingness (n=90). Further research should be conducted on a larger sample size with less
missingness to compare increased risk factors variables between tumor types, specifically prior
neoplasms. Neoplasms have been associated with a number of renal cell cancer syndromes that
are considered to increase the risk of PRCC. The most common renal cell cancer syndrome, von
Hippel-Lindau syndrome, is characterized by benign tumor growths and has a 40% chance of
developing renal cancer, including type 2 PRCC. Additionally, hereditary leiomyomatosis and
renal cell cancer (HLRCC), is characterized by harmatomas and also an increased risk of
developing type 2 PRCC (Paquin & Fasolino 2020; Modi & Singer 2016). Considering the
number of renal cell cancer syndromes that are both associated with an increased PRCC risk and
are characterized by neoplasms; further research should be conducted to determine if prior
neoplasms is a determining factor in PRCC subtype.
The findings in this study have potential implications for future treatment avenues. The
higher rate of MAPK pathway in type 1 supports the ongoing studies of the use of MET in
clinical trials. MET codes for c-Met, a tyrosine kinase protein that is involved with the MAPK
pathway. When c-Met binds to its ligand, HGF, a downstream cascade is started that leads to the
activation of the MAPK pathway which promotes cell migration and tumor proliferation (Zhang
et al. 2018). Seeing as 20% of type 1 tumors contain a MET mutation, it is not surprising that
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MAPK is the preferred pathway of type 1 tumors. Furthermore, the PI3K pathway was found to
be significant in the probability of having a type 2 tumor as well as being the preferred pathway
of type 2. The findings in this study support the ongoing efforts in determine drug treatment
therapies that target the PI3K pathway. PI3K is comprised of lipid kinases that once activated,
begin a downstream cascade that leads to cell growth and survival. PI3K pathway has a strong
association with the inactivation of PTEN, which has been correlated poor patient outcomes
(Yang et al. 2019; Bazzichetto et al. 2019).
Conclusion
Despite the imperfect database this study found that there is a trend in the data that is
clinically significant. Furthermore, this study provides the framework for future more
comprehensive research on the demographic, increased risk factor and genetic pathway
differences between PRCC type 1 and type 2 tumors. Future investigations should include a
more complete dataset with additional potential risk factors. Given the differences in survival
rates, such investigations will provide clinicians a better understanding of tumor types allowing
for quicker more accurate diagnosis and evidence based treatment plans.
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Fig. 4.2 Descriptive Statistics for Demographic Factors
Gender (n=158)
Male
Female
Race (n=149)
White
Black or African American
Other
Mean Age (n= 156)
Ethnicity (n= 144)
Hispanic or Latino
Not Hispanic or Latino

Type 1

Type 2

50
19

61
27

46
18
0
60 (Range 28 to 82)

66
15
4
64.5 (Range 28-88)

2
62

5
75

Fig. 4.3 Descriptive Statistics for Increased Risk Factors
Smoking History Category
(n=146)
1
2
3
4/5
Prior Neoplasm (n= 95)
Yes
No
Prior Malignancy (n= 156)
Yes
No
Mean BMI (n=123)

Type 1

Type 2

30
10
10
7

36
11
14
20

2
36

9
48

16
55
35.88

14
77
27.72

Fig. 4.4 Descriptive Statistics for Pathways
Pathway (n=157)
MAPK
HIPPO
PI3K
P53
WNT
NOTCH
TGF

Type 1

Type 2

31
2
8
13
7
5
2

23
3
27
16
6
9
3
67

TNF

1

1

Table 4.1. Demographics Model
OR
95% CI for OR
Age at Diagnosis
1.045
1.014
1.078
White
Reference
Black or African American
0.677
0.301
1.525
Other
5.601
0.54
58.089
Odds ratios (ORs) associated with the selected demographic model. The model was selected using
forward selection (criteria for entry p<.1) from a candidate model including age at diagnosis, race, sex,
and ethnicity. The final model had an effective sample size of 150.

Table 4.2. Increased Risk Factor Model
OR
Variable
Level
BMI
0.989
(n=121)
Smoke 1
Reference
Smoke
2
1.141
Smoking
(n=131)
Smoke 3
0.916
Smoke 4or 5
3.241
No
Reference
Malignancy
(n=150)
Yes
0.614
No
Reference
Neoplasm
(n=91*)
Yes
3.736

95% CI for OR
0.963

1.015

0.381
0.322
1.066
0.265
0.698

3.415
2.611
9.853
1.421
19.999

Odds ratios and associated confidence intervals for increased risk factor variables. Each variable, BMI,
smoking, malignancy and neoplasm were added to the demographic model (i.e. the model containing Age
at Diagnosis and Race) one at a time and the odds ratios for each variable and level are reported here,
controlling for age at diagnosis and race. Effective sample sizes are included under the variable labels.
Table 4.3. Pathway Model
Pathway
MAPK
HIPPO
NOTCH
P53
PI3K
TGF
TNF
WNT

OR
Reference
7.43
3.076
1.783
4.968
2.264
0.767
1.232

95% CI for OR
0.58
95.242
0.768
12.32
0.678
4.69
1.759
14.031
0.313
16.35
0.041
14.309
0.341
4.455
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Odds ratios and associated confidence intervals for individual pathways. Note that the CI for PI3K does
not contain 1 which indicates that PI3K is (significant and) positively associated with Type 2. ORs were
obtained by adding pathway to the demographic model controlling for age at diagnosis and race.

Fig. 4.5. Kaplan-Meier survival curve for type 1 PRCC tumors as compared to type 2 PRCC tumors.
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Chapter V
Synthesis of Manuscripts
Papillary renal cell carcinoma (PRCC) is the second most common renal cell carcinoma
(RCC), following clear cell, comprising of 15-20% of all RCCs. PRCC is a heterogenous disease
that consists of two histologically distinct subtypes; type 1 and type 2. PRCC is often
asymptomatic and difficult to detect with as many as 20-50% of tumors being discovered
incidentally (Marsaud et al 2015; Prochazkova et al. 2018). Furthermore, the treatment options
remain limited for PRCC tumors with nephrectomy continuing to be the preferred treatment.
Until recently research has been focused on the more common RCC subtype, clear cell.
Additionally, PRCC studies have been broadly based with little research being done on
comparing PRCC tumor subtypes. PRCC subtypes are genetically diverse and present with
varying patient outcomes (Fernandes & Lopes 2015; Pal et al. 2019). Considering that healthcare
providers are at the forefront of the diagnosis and treatment of PRCC, it is imperative that they
be able to distinguish between PRCC subtypes.
All the chapters in this dissertation work together to create a cohesive and comprehensive
understanding of PRCC as a whole, as well as understanding PRCC subtypes 1 and 2. The
purpose of this body of work was first to discuss the status of the current literature on PRCC
including subtypes, genetic underpinnings, epidemiology and treatment options. The second
purpose was to define what is known on differentiating between PRCC subtypes and to perform
a secondary data analysis to determine if there were clinically relevant differences between
PRCC type 1 and type 2 tumors.
In order to better understand PRCC as a disease, the first manuscript (chapter 2)
performed a comprehensive review and synthesis of the literature discussing the subtype
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classification, genetic pathways and epidemiology of the disease as it relates to clinicians. This
review found that PRCC is a genetically diverse disease with multiple subtypes. Currently, there
are two main histologically diverse subtypes; type 1 and type 2. Type 1 tumors are characterized
by a single layer of basophilic cells with sparse cytoplasm and small oval nuclei. Type 1 tumors
can be sporadic or hereditary and 20% of type 1 tumors present with a mesenchymal epithelial
transition (MET) gene variation (Marsuad et al. 2016). Conversely, type 2 tumors present with a
pseudostratified layer of cells with eosinophilic cytoplasm and large nuclei. Type 2 tumors can
also be sporadic or hereditary and have been associated with fumarate hydratase (FH) as well as
vascular endothelial growth factor (VEGF) gene variations (Modi and Singer 2015: TCGA,
2016: Marsuad et al. 2015). This literature review found that there is a lack of knowledge
concerning the epidemiology of type 1 and type 2 PRCC tumors. Furthermore, this review found
that PRCC tumors are treated the same as clear cell tumors with nephrectomy being the preferred
treatment method (Fernandes & Lopes 2015; Dengina et al. 2017). This manuscript differs from
the others in that it is a description of PRCC as whole and provides the necessary background for
manuscripts two and three.
After careful review of the literature, the second manuscript (chapter 3) aimed to further
examine the genetic underpinnings of PRCC tumors. The purpose of this literature synthesis was
to describe the various renal cell cancer syndromes that are associated with RCC. The most
common renal cancer syndrome is von Hippel-Lindau Syndrome which is characterized by
mutations in the VHL gene. Individual’s with von Hippel-Lindau Syndrome have a 40% chance
of developing an RCC, including the PRCC subtype (Gupta et al. 2017). Similarly, Hereditary
Leiomyomatosis and Renal Cell Cancer is characterized by mutations in the FH gene and has
been associated with the development of type 2 PRCC tumors (Arenas Valencia et al., 2017).
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Considering that numerous renal cancer syndromes present with benign neoplasms, this literature
review provided the basis for using prior neoplasms as a variable for the secondary data analysis
(Paquin & Fasolino 2020). The second manuscript differs from the first manuscript in that it
focuses specifically on hereditary causes of PRCC. Furthermore, this manuscript is a narrowbased literature review unlike manuscript 3, which is original research.
The third manuscript (chapter 4) in this dissertation performed a secondary data analysis
using The Cancer Genome Atlas- Kidney Renal Papillary Cell Carcinoma (TCGA-KIRP) data to
determine if there were significant differences between type 1 and type 2 PRCC tumors that can
be utilized by clinicians. The secondary data analysis focused on epidemiological factors, age,
ethnicity, gender, race; increased risk factors, body mass index (BMI), smoking history,
neoplasm history, and malignancy history; and tumor subtype pathway preference. This analysis
found that older age at diagnosis was significant in the probability of having a type 2 PRCC
tumor. Similarly, this study also found that being African American had a negative probability of
having a type 2 tumor. In terms of pathway preference, type 2 tumors were found to significantly
prefer the PI3K pathway and type 1 tumors utilized the MAPK pathway. Lastly, this study found
that there is a significant difference in overall survival rates between tumor types with type 2
tumors having a lower overall survival rate. Manuscript three is an original study that is based on
the literature reviews performed in manuscripts one and two.
Contribution to the Knowledge of PRCC and Healthcare Genetics
Up until recently research has been based on the clear cell subtype of RCC and what
research that has been done specifically on PRCC, has focused on the cellular molecular
components of the disease. Furthermore, there is a gap in the knowledge concerning the
clinically significant differences between type 1 and type 2 PRCC tumors (MacLennan & Cheng
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2020: Lineman et al 2015). This dissertation contributed to the current knowledge of PRCC by
determining that there are certain significant differences, age at diagnosis, race, genetic pathway
preference, and overall survival, between type 1 and type 2 PRCC tumors. The findings in this
dissertation are relevant to healthcare genetics because they provide the foundation for evidencebased practice concerning the diagnosis, prognosis and treatment of PRCC tumors. Furthermore,
this dissertation provides the background needed for future research initiatives that focus on
further defining the differences between type 1 and type 2 PRCC tumors.
Knowledge Gaps and Future Directions
Although this dissertation presented a comprehensive overview of PRCC and the
subtypes associated with the disease, there are still gaps in the knowledge. The first gap is that
although type 1 and type 2 PRCC tumors are the most recognized, there are more than two
subtypes associated with PRCC. Additionally, tumors can be heterogenous and present with
features of both type 1 and type 2 subtypes (Marsaud et al 2015; Prochazkova et al. 2018). This
dissertation was limited to the data currently available and therefore restricted to type 1 and type
2 PRCC tumors, not accounting for additional subtypes. Another limitation was that this
dissertation did not cover all known renal cancer syndromes. There are other syndromes,
specifically hereditary papillary renal cell carcinoma (HPRCC) which is characterized by MET
variations, that predispose individual’s to PRCC. Although quite rare, HPRCC is associated with
an almost 100% chance of developing type 1 PRCC tumors (Maher 2018). This dissertation
focused on the most common renal cancer syndromes and is not a comprehensive list. Lastly,
this dissertation was limited to a small sample population of already collected data, thus the
research questions were limited to those that could be answered by the available data.
Additionally, the sample size was further limited with each variable tested in the final
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manuscript. This means that a larger sample size could provide additional insights into variables
that can distinguish between type 1 and type 2 PRCC tumors.
The findings in this study indicate the need for further research to better distinguish
between type 1 and type 2 PRCC subtypes. First there has to be research to clearly designate
what constitutes PRCC subtypes. Type 1 and type 2 subtypes have consistently been recognized
as the primary PRCC subtypes. However, these two subtypes have been characterized by their
histology and a recent study has proposed other options for tumor typing (Mager et al. 2019).
Having a clear system to properly subtype PRCC tumors is needed to insure the validity of future
PRCC research.
Second, there is a need for a new descriptive and comprehensive PRCC dataset.
Currently, the TCGA-KIRP remains the only source for a large collection of PRCC data that
includes clinical, genetic and risk factor information. However, this dataset is largely incomplete
and the last sample was collected in 2013 (Lineman et al, 2016). There is a need for new research
that is more current and is comprised of more complete increased risk factor data, including
chemical exposure, prior neoplasms, renal cancer syndrome status, and smoking history.
Furthermore, this study must also include the specific subtype of each PRCC tumor as defined by
the current literature.
Thirdly, additional research on PRCC preferred genetic pathways should be conducted to
better understand what role pathways play in determining PRCC subtypes. Pathway preference is
important in the development of tumor specific treatment options. Given the heterogenous nature
of both types of PRCC, understanding the preferred genetic pathways of each subtype will lead
to better evidence-based treatment options. Current clinical trials are focused on specific genes
(namely MET) or individuals with certain renal cancer syndromes (Clinicaltrials.gov, 2020).
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Focusing treatment research on genetic pathways as opposed to specific genes, will lead to the
ability to treat a larger variety of PRCC tumors.
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List of Acronyms
Cancers
ccRCC – Clear Cell Renal Cell Carcinoma
ccPRCC= Clear Cell Papillary Renal Cell Carcinoma
PRCC – Papillary Renal Cell Carcinoma
RCC – Renal Cell Carcinoma
Genes/Proteins
BAP1 - BRCA1 Associated Protein-1
BRCA1 = Breast Cancer type 1 Susceptibility Protein
EGFR = Epidermal Growth Factor Receptor
FH- Fumarate Hydratase
FLCN – Folliculin
FRA7G = Aphidicolin-Inducible Fragile Site
HER2 = human epidermal growth factor receptor 2
HGF = Hepatocyte growth factor
HIC-1 = Hypermethylated in Cancer 1
KLLN = Killin
MET – Mesenchymal Epithelial Transition
MITF = Melanocyte Inducing Transcription Factor
P53 = Tumor Protein 53
PTEN = Phosphatase and Tensin Homolog
RTK = Tyrosine Kinase Receptor
SDH = Succinate Dehydrogenase Complex Iron Sulfur
SDHB = Succinate Dehydrogenase Complex Iron Sulfur Subunit B
SDHD = Succinate Dehydrogenase Complex Iron Sulfur Subunit D
TAU= microtubule-associated protein tau
TOP2A= topoisomerase 2-alpha
TSC1- TSC Complex Subunit 1
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VEGF = Vascular Endothelial Growth Factor
VHL - Von Hippel–Lindau tumor suppressor
Pathways
MAPK = Mitogen Activated Protein Kinase
P53 = Tumor Protein 53 pathway
PI3K = Phosphoinositide 3-kinases
TGF = Transforming growth factor beta
TNF = Tumor Necrosis Factor
WNT = blending of Wingless and Int-1
Syndromes/Diseases
BHD = Birt-Hogg-Dubé Syndrome
CS = Cowden Syndrome
ESRD = End Stage Renal Disease
HRLCC= Hereditary Leiomyomatosis and Renal Cell Cancer
HNPCC = Lynch Syndrome/ Hereditary Non-Polyposis Colorectal Cancer
HPRCC = Hereditary Papillary Renal Cell Carcinoma
TSC = Tuberous Sclerosis Complex
VHL = von Hippel-Lindau Disease
Databases
BCR= Biospecimen Core Resource
cBioPortal = cBioPortal for cancer genomics
TCGA-KIRP- The Cancer Genome Atlas- Kidney Renal Papillary Cell Carcinoma
Terms
BMI – Body Mass Index
CNA = Copy Number Alteration
CI = Confidence Interval
OR = Odds Ratio
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